Keywords: SkyePharma, Flutiform, Mundipharma, Asthma, MAA, Europe
Flutiform review to take longer than expected, says SkyePharma
Article | 19 October 2011
UK-based SkyePharma (LSE: SKP) revealed yesterday that the review of the European Marketing Authorization Application for Flutiform, a fixed-dose combination ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- New study shows UCB's Neupro reduces NSBP in RLS patient
